Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes

Arthritis Rheum. 2008 Mar;58(3):649-56. doi: 10.1002/art.23260.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use*
  • Cell Proliferation / drug effects
  • Etanercept
  • Humans
  • Immunoglobulin G / pharmacology
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Osteoclasts / drug effects
  • Osteoclasts / pathology
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Spondylitis, Ankylosing / complications
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / pathology*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept